Veriti Management LLC Seagen Inc. Transaction History

Veriti Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$191.51 - $216.16 $32,939 - $37,179	-172 Reduced 4.88%	3,350 $710,000
Q2 2023 Jul 13, 2023	SELL	$187.64 - $206.25 $282,585 - $310,612	-1,506 Reduced 29.95%	3,522 $677,000
Q1 2023 Apr 26, 2023	BUY	$127.59 - $203.08 $127,334 - $202,673	998 Added 24.76%	5,028 $1.02 Million
Q4 2022 Jan 20, 2023	BUY	$117.37 - $139.17 $240,960 - $285,716	2,053 Added 103.84%	4,030 $0
Q3 2022 Oct 26, 2022	SELL	$135.27 - $180.11 $68,446 - $91,135	-506 Reduced 20.38%	1,977 $271,000

Q2 2022 Jul 18, 2022	BUY	$108.81 - $179.33 $15,015 - $24,747	138 Added 5.88%	2,483 $439,000
Q1 2022 Apr 11, 2022	BUY	$119.61 - $157.85 $11,243 - $14,837	94 Added 4.18%	2,345 $338,000
Q4 2021 Jan 19, 2022	SELL	$142.57 - $190.86 $5,275 - $7,061	-37 Reduced 1.62%	2,251 $348,000
Q3 2021 Oct 08, 2021	BUY	$142.45 - $169.82 $24,643 - $29,378	173 Added 8.18%	2,288 $389,000
Q2 2021 Jul 13, 2021	BUY	$135.08 - $161.1 $84,830 - $101,170	628 Added 42.23%	2,115 $334,000
Q1 2021 Apr 14, 2021	BUY	$137.51 - $190.8 $5,637 - $7,822	41 Added 2.84%	1,487 $206,000
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $238,054 - $306,450	1,446 New	1,446 $253,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Veriti Management LLC, based on Form 13F filings with the SEC.

Stay updated on Veriti Management LLC with notifications on news.